| MannKind to Present at Upcoming Investor Conferences |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City: |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript |
MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Conference Call Participants Olivia Brayer – Cantor Anish Nikhanj – RBC Andreas Argyrides – Oppenheimer & Co. Yun Zhong – Wedbush Anthony Petrone – Mizuho Operator Good morning, and welcome to the MannKind Corporation First Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on May 08, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days. |
seekingalpha.com |
2025-05-08 15:34:28 |
Czytaj oryginał (ang.) |
| MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates |
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago. |
zacks.com |
2025-05-08 14:25:22 |
Czytaj oryginał (ang.) |
| MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update |
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v. |
globenewswire.com |
2025-05-08 12:05:00 |
Czytaj oryginał (ang.) |
| MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options |
Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2025-04-07 16:30:00 |
Czytaj oryginał (ang.) |
| MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 |
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 |
globenewswire.com |
2025-03-10 08:05:00 |
Czytaj oryginał (ang.) |
| MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question |
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential expansion into IPF and MannKind's in-house developments in NTM-LD and IPF present significant growth opportunities despite competitive threats. MannKind's financial health is solid, with strong liquidity and manageable debt, supporting ongoing R&D and potential market expansion. |
seekingalpha.com |
2025-02-27 12:32:00 |
Czytaj oryginał (ang.) |
| MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript |
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & Renshaw Yun Song - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days. |
seekingalpha.com |
2025-02-26 23:09:40 |
Czytaj oryginał (ang.) |
| Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-26 22:31:11 |
Czytaj oryginał (ang.) |
| MannKind (MNKD) Q4 Earnings Meet Estimates |
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago. |
zacks.com |
2025-02-26 21:15:25 |
Czytaj oryginał (ang.) |
| MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. |
globenewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics |
Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-02-24 12:21:29 |
Czytaj oryginał (ang.) |
| MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| MoneyShow's Best Investment Ideas For 2025: Part 8 |
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 8 includes American Superconductor, Skye Bioscience, Healwell AI, Dell Technologies, MicroStrategy and MannKind, among others. |
seekingalpha.com |
2025-02-03 11:20:00 |
Czytaj oryginał (ang.) |
| MannKind Expands Executive Leadership Team |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025. |
globenewswire.com |
2025-01-06 18:30:00 |
Czytaj oryginał (ang.) |
| MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets |
MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. |
seekingalpha.com |
2024-12-17 09:16:35 |
Czytaj oryginał (ang.) |
| MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) |
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. |
globenewswire.com |
2024-12-16 08:05:00 |
Czytaj oryginał (ang.) |
| CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India |
India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd. |
globenewswire.com |
2024-12-11 08:00:00 |
Czytaj oryginał (ang.) |
| MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript |
MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas Argyrides - Oppenheimer Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcome to the MannKind Corporation Third Quarter 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2024, and will be available on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days. |
seekingalpha.com |
2024-11-07 22:30:36 |
Czytaj oryginał (ang.) |
| MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say |
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-07 22:01:23 |
Czytaj oryginał (ang.) |
| MannKind (MNKD) Matches Q3 Earnings Estimates |
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago. |
zacks.com |
2024-11-07 20:41:12 |
Czytaj oryginał (ang.) |
| MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update |
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. |
globenewswire.com |
2024-11-07 18:02:00 |
Czytaj oryginał (ang.) |
| MannKind to Present at 2024 UBS Healthcare Conference |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2024-11-05 18:15:00 |
Czytaj oryginał (ang.) |
| MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases |
Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2024-11-04 08:05:00 |
Czytaj oryginał (ang.) |
| MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? |
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-01 12:16:09 |
Czytaj oryginał (ang.) |
| MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2024-10-31 18:05:00 |
Czytaj oryginał (ang.) |
| First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease |
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease |
globenewswire.com |
2024-10-30 23:00:00 |
Czytaj oryginał (ang.) |
| Why MannKind (MNKD) Could Beat Earnings Estimates Again |
MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-10-07 17:15:28 |
Czytaj oryginał (ang.) |
| MannKind (MNKD) Just Overtook the 20-Day Moving Average |
MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a short-term bullish trend. |
zacks.com |
2024-10-04 14:37:16 |
Czytaj oryginał (ang.) |
| MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion |
MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. |
seekingalpha.com |
2024-10-03 12:00:00 |
Czytaj oryginał (ang.) |
| More Adults With Type 1 Diabetes Achieved A1C Goal ( |
30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association's 84 th Scientific Sessions Switching to, or remaining on Afrezza allowed twice as many people to get to goal during the extension phase DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2024-09-30 10:00:00 |
Czytaj oryginał (ang.) |
| MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease |
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment |
globenewswire.com |
2024-09-18 10:15:00 |
Czytaj oryginał (ang.) |
| MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Financial Officer Chris Prentiss and Dr. Wasim Fares Therapeutic Area Head, Orphan Lung Diseases, will share updates during a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York. |
globenewswire.com |
2024-09-10 20:30:00 |
Czytaj oryginał (ang.) |
| MannKind to Present at Upcoming Conferences |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during fireside chats at three upcoming investor conferences: |
globenewswire.com |
2024-08-27 20:30:00 |
Czytaj oryginał (ang.) |
| Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board |
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. |
globenewswire.com |
2024-08-14 12:00:00 |
Czytaj oryginał (ang.) |